In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...

Discover how remote assessments, wearables, and digital technologies can decentralize data collection, reduce patient burden, and enable trials to reach more diverse and representative populations.

Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...

See how combining human oversight with AI insights improves protocol authorship, site selection, and monitoring strategies, ...

In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...

And the FDA has approved Amgen’s Uplizna for adults with antibody-positive generalized myasthenia gravis, adding a ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...

Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...

ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...